To evaluate the implementation of a novel algorithm-based discharge programme for the community follow-up of men with prostate cancer.
Introduction
Prostate cancer is the most common malignancy in UK men, accounting for 26% of all male cancer diagnoses in the UK, and the incidence is rising [1, 2] . Survival after diagnosis is typically prolonged. One study in 2010-2011 estimated an 84% 10-year survival for newly diagnosed men in England and Wales [3] . The prevalence of prostate cancer in the UK is therefore set to rise: a recent study predicted an increase from the current position of 255 000 men in 2014, to 416 000 in 2020 and 620 000 in 2030 [4] . Such inflation will significantly impact upon NHS resources, and in particular on urology outpatient clinic attendances, of which prostate cancer follow-up makes up a significant proportion.
Currently, most patients are followed-up in secondary care, typically in consultant-led clinics; however, as demand increases this traditional model of regular review will increasingly become untenable. Such a realisation has prompted the introduction of a range of innovative models of follow-up, of which specialist nurse-led prostate cancer review has been most rigorously evaluated. To date, two randomised trials have been performed, both concluding that nurse-led clinics provide a safe alternative to consultant-led follow-up [5, 6] . The role of primary care as a provider of safe, reliable oncological follow-up has been less well investigated, although the benefits in terms of reduced costs are well established [7] [8] [9] , and improved patient satisfaction rates have been reported by some authors [10] . However, there are a number of concerns regarding the delegation of prostate cancer followup, including a risk that care may be duplicated or poorly coordinated [4, 11] , a failure of compliance with community follow-up algorithms, and reduced access to specialist nursing services [12] .
At our institution, the routine review of men with prostate cancer was identified as a major contributing factor to reduced outpatient capacity and adverse new follow-up ratios. Many asymptomatic men were attending for PSA surveillance alone after definitive management of prostate cancer, and not uncommonly expressed dissatisfaction at long clinic waits, short appointments, and limited medical input. Whilst the discharge of such patients from secondary care represented an opportunity to improve capacity, an unregulated return to primary care was clearly undesirable. After extensive negotiations with representatives of all four local clinical commissioning groups, an ongoing algorithmbased prostate cancer locally enhanced service (LES) was introduced in April 2012. In the present report, we describe our initial experience with ≥12 months of follow-up.
Patients and Methods
Before the introduction of the LES, an extensive education programme for Nottinghamshire primary care practitioners was undertaken, under the aegis of Nottingham City Clinical Commissioning Group. A number of profile-raising events were locally convened, and GPs were also directly contacted about the initiative via e-mail and newsletter. Subsequently, GPs were given online and paper access to LES discharge pathways and management algorithms for review in primary care. Patients with prostate cancer at Nottingham University Hospitals NHS Trust were identified for discharge from consultant-led and clinical nurse-specialist telephone clinics onto one of four discharge pathways: watchful waiting, androgen-deprivation therapy (ADT), post-prostatectomy, and post-radiotherapy (Fig. 1A-D) . Patients under active surveillance were retained under consultant-led follow-up in secondary care.
The algorithm for the watchful-waiting pathway is shown in Fig. 1A . Criteria for discharge comprised asymptomatic status and a negative bone scan for metastatic disease. Patients were discharged with a clearly stated physician-defined PSA level threshold for re-referral back to secondary care, and were required to attend for 6-monthly community symptom review with PSA and alkaline phosphatase (ALP) level testing. Triggers for re-referral were a PSA level rise above threshold, new LUTS, significant anxiety, or a positive GP-organised bone scan.
The ADT pathway algorithm is shown in Fig. 1B . A significant PSA response after commencement of ADT, defined as a fall of at least 75% at 3 months, was required for discharge. Non-responders or partial responders were retained in secondary care for continued follow-up. Patients were required to attend for 6-monthly community symptom review with PSA and ALP level testing. Patients required re-referral if their PSA nadir was <10 ng/mL and had risen above a threshold of 10 ng/mL, if their PSA nadir was >10 ng/mL and had risen by >20%, or if a GP-arranged bone scan was positive for metastatic disease. GPs were requested to check serum testosterone in PSA-relapsed patients at the time of rereferral.
Men were discharged on the post-prostatectomy algorithm (Fig. 1C) if they were at least 2 years post-radical prostatectomy with a PSA level of <0.1 ng/mL and no ongoing clinical issues, in accordance with National Institute for Health and Care Excellence (NICE) guidelines [1] . They were required to undergo 6-monthly PSA level testing for 3 years, followed by annual assessment thereafter. Criteria for rereferral comprised a PSA level of >0.1 ng/mL or significant new symptoms.
The post-radiotherapy pathway algorithm is shown in Fig. 1D . Men were discharged after radical external beam radiotherapy either after completion of adjuvant ADT, or with explicit recommendations for the timing of ADT cessation. Patients were required to have 6-monthly PSA and testosterone level tests for 3 years, followed by annual assessments thereafter. Criteria for re-referral comprised a PSA level rise above a single threshold value of 2 ng/mL on two occasions 1 month apart, or if there were concerns over urinary or rectal toxicity.
After discharge a formal letter, along with a further copy of the relevant pathway, was sent to both GP and patient, and the patient was registered on two separate databases located in primary and secondary care respectively. Pre-arranged governance measures ensured regular crosschecking of databases and scheduled formal audit at 12, 18, and 24 months. For audit purposes, the patient, and the patient was registered on point was defined as the number of surviving men remaining under primary care follow-up without re-referral. Attributable cause of death was meticulously determined by the following methods: for men who died in hospital, cause of death was determined from hospital records; the Coronernsured regular crosschecking of databases and scheduled formalGPs were given ommunity deaths, the local registrar of births and deaths and individual GPs were contacted. For men achieving PSA-threshold criteria during follow-up, yet for whom a re-referral was not forthcoming, GPs were contacted to arrange community review and re-referral as deemed appropriate. For discharged men with no recorded follow-up, liaison with primary care providers was performed for clarification purposes. In this way, oncological and surveillance outcomes were determined for all discharged patients. 
Results
From April 2012 to July 2014, 573 men were discharged across all four pathways: 169 on watchful-waiting pathway, 229 on the ADT pathway, 95 on the post-prostatectomy pathway, and 80 on the post-radiotherapy pathway. All patients had ≥12 months of follow-up.
In all, 169 men were discharged on the watchful-waiting pathway (Table 1) , of whom 86 (51.1%) underwent a bone scan before discharge. In all, 74 (43.7%) men were discharged with explicit recommendations for re-referral and 62 with a defined PSA threshold. At 6, 12, 18, and 24 months, 92.1%, 96.1%, 83.2%, and 86.0% men, respectively, underwent PSA level testing. PSA-threshold breaches were identified in eight men, of whom seven were re-referred appropriately. The remaining patient refused further treatment and referral. Appropriate ALP testing was performed in 56.1%, 53.2%, 42.0%, and 56.1% at 6, 12, 18, and 24 months, respectively. Of these, 22 (8.6%) men had a raised ALP above the normal range, but only four (18.2%) were re-referred appropriately, of whom two had a bone scan organised in the community before re-referral. In all, 23 men died during follow-up, with prostate cancer as the attributable cause of death in six (26.1%): of these four were under secondary palliative care at the time of death and two were GP-certified community deaths with PSA and ALP values below threshold. Only two men were identified as having no recorded follow-up at any time point: one patient refused further follow-up and the other was considered too unwell for regular review.
In all, 229 men were discharged on the ADT pathway ( Table 2 ). At 6, 12, 18, and 24 months, 95.5%, 99.5%, 91.7%, and 89.1% patients, respectively, underwent PSA level testing. PSA-threshold breaches were identified in 40 men: of these, 37 (92.5%) were promptly re-referred, although only eight (21.6%) had a testosterone level assessment before re-referral. Of the remaining three men, there were two refusals and one late referral at 4 months. In this latter case, the PSA level had remained stable and he was subsequently commenced on second-line hormone therapy 3 months after re-assessment in secondary care. Only one patient had no recorded follow-up, due to relocation. There were 45 deaths in the group, of * All Patients, whether responders or non-responders will be referred back to GP for GnRH injections and can all be included in register ** Nadir PSA = lowest PSA level following diagnosis *** Triptorelin is currently recommended by the Area Prescribing Committee (APC) which 14 (31.1%) were attributed to prostate cancer. Of these, 13 were expected deaths following disease progression and appropriate re-referral to secondary urological, oncological, or palliative care services. The remaining patient died unexpectedly following hospital admission with presumed metastatic PSA non-secreting prostate cancer.
In all, 95 men were discharged on the post-prostatectomy pathway (Table 3 82.6%, 82.3%, and 74.2% of men, respectively, underwent PSA level testing. PSA-threshold breaches were identified in four men, two of whom were re-referred appropriately. A late referral at 4 months subsequently resulted in the administration of adjuvant radiotherapy several months after re-referral. The remaining patient was medically unwell at the time of his PSA level assessment and subsequently died from a respiratory related illness, the only registered death in this group. There were four men with no recorded follow-up; two were due to relocation, but the remaining two men were genuinely lost to follow-up, due to non-registration on the primary care database. Both men were subsequently recalled for appropriate PSA surveillance, neither of whom had a PSA-threshold breach.
In all, 80 patients were discharged on the post-radiotherapy pathway (Table 4) . At 6, 12, 18, and 24 months, 93.8%, 89.9%, 91.4%, and 91.9% men, respectively, underwent PSA level testing. There were two PSA-threshold breaches, both of which were re-referred appropriately. Two men had no recorded follow-up; one had relocated but the other was considered genuinely lost to follow-up and was recalled with no identifiable PSA-threshold breach. Two patients died during follow-up from causes unrelated to prostate cancer.
Discussion
The traditional model of routine prostate cancer follow-up in secondary care is considered safe, but is unquestionably burdensome on limited NHS resources. Whilst several alternate models have been proposed, to date only two randomised trials have assessed novel approaches to the follow-up of men with prostate cancer. Both utilised specialist urology nurse-led clinics [5, 6] and both concluded that the models were a cost-effective and safe alternative to standard consultant-led follow-up. However, there were a number of limitations. In the study described by Helgesen et al. [5] , there were no reported differences in safety or patient 2/3 0/1 n/a n/a Failure to refer due to PSA-threshold breach, n/N 1/3 1/1 n/a n/a Number of patients who died n/a 1 n/a n/a n/a n/a n/a Failure to refer due to PSA-threshold breach, n/N 0/2 n/a n/a n/a Number of patients who died n/a n/a 2 n/a satisfaction when nurse-led and consultant-led prostate cancer clinics were compared. However, monitoring regimes and attendance intervals were significantly different between the two groups, and patient safety reporting was defined as complication frequency and lag time from symptoms to intervention, with no PSA level monitoring or measure of symptom-free local progression. In the randomised study by Faithfull et al. [6] , patients with prostate cancer and bladder cancer treated with radical radiotherapy were randomised to either nurse-led or consultant-led review, with no reported difference in patient satisfaction levels. Whilst the authors highlight the economic benefits and excellent patient satisfaction levels associated with nurse-led clinics, the study only involved patients with bladder and prostate cancer undergoing radiotherapy treatment, and as such the findings are not necessarily transferable to the long-term follow-up of men with prostate cancer. In addition, whilst both studies indicate that nurse-led clinics are feasible and acceptable; men were still retained in secondary care facilities and ultimately were not discharged. To our knowledge, our present study is the first to describe the outcomes of an algorithm-based discharge schedule for the community follow-up of men with prostate cancer.
Overall, there was good compliance with PSA level monitoring across all four discharge pathways, with most men receiving blood tests at appropriate intervals. Occasionally, community PSA level tests were missed or performed late and this is reflected in the reported compliance figures. However, this occurrence is arguably no different to that seen in secondary care and almost all patients subsequently remained under regular community PSA level review. Indeed, across all four pathways, including 573 men in total, there were only seven with no recorded follow-up, of whom four had moved out of the local area. Three were genuinely lost to follow-up, all due to non-registration, and whilst there was no perceived harm in any of the three cases, we have since introduced more stringent database cross-reference measures to prevent similar occurrences in the future.
Compliance with ALP level testing was much poorer than for PSA level testing, with only about one half of men undergoing regular blood tests. Community access bone scanning and testosterone evaluation were also underutilised. The reasons for such omissions are not entirely clear, but the finding emphasises the importance of regular and repeated GP education events. Indeed, an early 12-month audit detailing some of the above findings precipitated a second round of GP education events, with further feedback/ education sessions scheduled for 24 months. Notwithstanding education issues, patient factors are also likely to have played a role. Although we were careful to involve men in the discharge decision and shared with them copies of discharge letters and post-discharge follow-up algorithms, most men tended to focus on the importance of the PSA level test, and were perhaps less likely to question seemingly lesser omissions.
An overriding priority of clinicians involved in the delegation of care pathways is that patients are not subject to undue harm. This was the primary consideration of the present study, one which provides justification for the diligent approach to patient outcome reporting described herein. Overall, we believe that our present findings are consistent with safe oncological practice. For example, there was excellent compliance for the re-referral of PSA-threshold breaches. Indeed, 48 of 54 (88.9%) men were re-referred promptly to secondary care after PSA-threshold breach. Of the remaining six patients, there were three refusals, one unrelated death before referral, and two late referrals at 4 months, each with no perceived harm. Similarly there were only three unexpected deaths attributed to prostate cancer. Of these, two patients on the watchful-waiting pathway died in the community with GP-issued death certificates indicating the primary cause of death to be prostate cancer. In both cases there was no suggestion of PSA or ALP progression on serial testing, and in the absence of post-mortem examinations for either case, it is difficult to be entirely sure of the true cause of death. Certainly it is unlikely that secondary care review would have affected the outcome in the absence of clear prostate cancer progression. The remaining patient died of a presumed progressive PSA non-secreting prostate cancer before scheduled community interval testing, and as such it is likely that he would have presented as an interval emergency between secondary care outpatient appointments.
Before implementation, a comprehensive community education programme was initiated, including a number of formal GP education events, with regular mailshots and reminders. However, as with any other new initiative, awareness was slow to develop, with a noticeable spike in communication from primary care seeking clarification on a number of points of discharge. This was particularly evident for men discharged on the watchful-waiting pathway, compounded by a failure of secondary care clinicians to set clear criteria for re-referral, or indeed to arrange bone scans before discharge. Indeed, it could be argued that whilst GP colleagues and patients themselves were fastidious in their compliance with follow-up arrangements, secondary care clinicians performed less well when adhering to discharge guidelines. A clear lesson learned is that secondary care education initiatives should be at least as thorough as those employed in primary care. In order to address this deficiency repeated audit and education sessions were convened in secondary care, with targeted dissemination of follow-up algorithms to key decision-makers.
Whilst there are several strengths of the present study, including robust governance strategies and meticulous
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© 2016 The Authors BJU International © 2016 BJU International attention to the determination of individual patient outcomes, there are some limitations. Firstly, there are relatively small numbers of men with extended follow-up, and whilst shortterm oncological safety appears secure, no conclusion can be made regarding longer-term follow-up.
Certainly it is conceivable that compliance with follow-up might reduce over time, and in this regard further reporting of mature data will be required. Secondly, although similar models elsewhere have been associated with acceptable rates of patient satisfaction [5, 6] , this has not been formally assessed in the present study, nor indeed have we explored satisfaction levels in primary care. Finally, although a desire to improve adverse new:follow-up clinic appointment ratios was a fundamental driver for the initiative, the impact on outpatient efficiency has not been directly examined, although the discharge of almost 600 patients from oversubscribed clinics has undoubtedly had a major impact.
In conclusion, we believe this is the first reported study of its kind to examine the outcomes of a dedicated community follow-up protocol in men with prostate cancer. Initial results suggest that the novel algorithm-based schedule described herein is a viable, effective, and oncologically safe method for the controlled discharge of men from secondary to primary care. Longer-term follow-up, patient satisfaction data, and economic evaluation, are however required to assess the true impact of the initiative.
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